수지상세포 암백신 시장 규모는 향후 수년간 연평균 10.1%의 성장률로 2029년까지 40억 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 오믹스 기술의 통합, 세계 고령화, 디지털 건강 솔루션의 출현, 환자 지원 활동 및 인식 제고 캠페인 증가, 인공지능(AI)의 통합, 바이오마커 기반 치료에 대한 집중 등에 기인하는 것으로 보입니다. 예측 기간 중 주요 동향으로는 재생의료의 발전, 약물전달 시스템의 혁신, 환자 중심의 의약품 개발, 새로운 항원 발굴의 진전, 차세대 백신 플랫폼 개발 등을 꼽을 수 있습니다.
수지상세포 암백신 시장은 암 발병률 증가로 인해 성장할 수 있는 태세를 갖추고 있습니다. 비정상적인 세포의 무질서한 증식을 특징으로 하는 암은 생활습관, 환경적 요인, 유전적 소인 등 다양한 요인에 의해 영향을 받습니다. 수지상세포 암백신은 암세포를 표적으로 삼아 신체의 면역체계를 활성화시킴으로써 암 치료에 중요한 역할을 할 수 있으며, 환자의 예후를 개선할 수 있습니다. 예를 들어 세계보건기구(WHO)의 예측에 따르면 2050년까지 암 환자가 크게 증가할 것으로 예상되며, 이러한 증가하는 의료 문제를 해결하기 위해 수지상세포 암백신과 같은 혁신적 치료법이 시급히 필요하다고 강조하고 있습니다.
수지상 세포 암백신 시장의 주요 업체들은 치료 효과가 높은 암백신을 개발하고 환자의 임상 치료를 강화하기 위해 전략적 파트너십을 적극적으로 형성하고 있습니다. 상호 사업 목표를 달성하기 위한 이러한 제휴는 백신 개발을 가속화하기 위한 자원과 전문 지식의 융합을 촉진합니다. 예를 들어 월터 앤 일라이자 홀 의학연구소는 피터 맥컬럼 암센터(Peter McCallum Cancer Center)와 파트너십을 맺고 치료 옵션이 제한적인 환자들을 위한 암백신 개발을 위해 막대한 자금을 지원받고 있습니다. 이 공동 연구는 30년 전에 수행된 선구적인 연구를 기반으로 하고 있으며, 암 환자를 위한 획기적인 임상시험을 시작할 수 있는 잠재력을 가지고 있습니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 - 금리, 인플레이션, 지정학, Covid 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
- 세계 수지상세포 암백신 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
- 최종 용도 산업의 분석
- 세계의 수지상세포 암백신 시장 : 성장률 분석
- 세계의 수지상세포 암백신 시장 실적 : 규모와 성장, 2019-2024
- 세계의 수지상세포 암백신 시장 예측 : 규모와 성장, 2024-2029, 2034F
- 세계 수지상세포 암백신 TAM(Total Addressable Market)
제6장 시장 세분화
- 세계의 수지상세포 암백신 시장 : 제품별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- CreaVax
- Sipuleucel-T(Provenge)
- 기타 제품
- 세계의 수지상세포 암백신 시장 : 유통 채널별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 병원
- 암센터
- 외래 수술 센터
- 클리닉
- 세계의 수지상세포 암백신 시장 : 용도별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 소아과
- 성인
- 세계의 수지상세포 암백신 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 종양학
- 조사기관
- 바이오의약품 기업
- 세계의 수지상세포 암백신 시장, Creavax의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 임상시험에서의 Creavax
- Creavax 상업화
- 세계의 수지상세포 암백신 시장, Sipuleucel-T(Provenge)의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 전립선암에서의 Sipuleucel-T
- Sipuleucel-T 시장 점유율
- Sipuleucel-T의 규제 승인
- 세계의 수지상세포 암백신 시장, 기타 제품의 서브 세분화, 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- Dcvax
- Oncovax
- GVAX
- 기타 실험적 수지상세포 백신
제7장 지역별·국가별 분석
- 세계의 수지상세포 암백신 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
- 세계의 수지상세포 암백신 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
- 수지상세포 암백신 시장 : 경쟁 구도
- 수지상세포 암백신 시장 : 기업 개요
- Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
- Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
- Cognate BioServices Inc. Overview, Products and Services, Strategy and Financial Analysis
- APAC Biotech Overview, Products and Services, Strategy and Financial Analysis
- Asterias Biotherapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
- Batavia Biosciences
- Medigene AG
- Zelluna Immunotherapy AS
- Diakonos Oncology
- Elios Therapeutics LLC
- Northwest Biotherapeutics
- Oncopep Inc.
- PDC*line Pharma SA
- SillaJen Biotherapeutics Inc.
- VLP Therapeutics
- ImmunityBio Inc.
- Celldex Therapeutics Inc.
- Bellicum Pharmaceuticals
- Argos Therapeutics Inc.
- DCPrime
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
- 수지상세포 암백신 시장 2029 : 새로운 기회를 제공하는 국가
- 수지상세포 암백신 시장 2029 : 새로운 기회를 제공하는 부문
- 수지상세포 암백신 시장 2029 : 성장 전략
제36장 부록
KSA
Dendritic cell cancer vaccines are immunotherapies that leverage the body's dendritic cells to stimulate an immune response against cancer cells, potentially enhancing the body's ability to recognize and destroy tumors. They represent a personalized treatment approach tailored to target specific types of cancer, aiming to bolster the immune system's capacity to combat the disease. By harnessing the body's immune system, dendritic cell cancer vaccines hold promise for eliciting more effective and durable responses in patients.
The main products in the realm of dendritic cell cancer vaccines include CreaVax, Sipuleucel-T (Provenge), and others. CreaVax is a dendritic cell cancer vaccine crafted to activate the body's immune response against cancer cells, employing specialized immune cells loaded with tumor-specific antigens. These products are typically distributed through hospitals, cancer centers, ambulatory surgical centers, and clinics, with applications extending to both pediatric and adult populations. End users encompass oncology practitioners, research institutions, and biopharmaceutical companies alike.
The dendritic cell cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides dendritic cell cancer vaccine market statistics, including the dendritic cell cancer vaccine industry global market size, regional shares, competitors with the dendritic cell cancer vaccine market share, detailed dendritic cell cancer vaccine market segments, market trends, and opportunities, and any further data you may need to thrive in the dendritic cell cancer vaccine industry. These dendritic cell cancer vaccine market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The dendritic cell cancer vaccine market size has grown rapidly in recent years. It will grow from $2.46 billion in 2024 to $2.71 billion in 2025 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to cancer awareness initiatives, investments in manufacturing infrastructure, exploration of combination therapies, adoption of precision medicine, and improved understanding of the immune system.
The dendritic cell cancer vaccine market size is expected to see rapid growth in the next few years. It will grow to $4 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to integration of omics technologies, global aging population, emergence of digital health solutions, increasing patient advocacy efforts and awareness campaigns, integration of artificial intelligence (ai), focus on biomarker-driven therapies. Major trends in the forecast period include regenerative medicine advances, innovations in vaccine delivery systems, patient-centric drug development, advances in neoantigen identification, development of next-generation vaccine platforms.
The dendritic cell cancer vaccine market is poised for growth driven by the increasing incidence of cancer cases. Cancer, characterized by the uncontrolled proliferation of abnormal cells, is influenced by various factors including lifestyle choices, environmental factors, and genetic predispositions. Dendritic cell cancer vaccines play a crucial role in cancer treatment by activating the body's immune system to target cancer cells, potentially leading to improved patient outcomes. For example, projections from the World Health Organisation suggest a substantial increase in cancer cases by 2050, highlighting the urgent need for innovative treatments such as dendritic cell cancer vaccines to address this growing healthcare challenge.
Key players in the dendritic cell cancer vaccine market are actively engaged in forming strategic partnerships to advance the development of curative cancer vaccines and enhance clinical care for patients. These collaborations, aimed at achieving mutual business objectives, facilitate the pooling of resources and expertise to accelerate vaccine development. For instance, the Walter and Eliza Hall Institute of Medical Research partnered with the Peter MacCallum Cancer Centre to receive substantial funding for the development of a cancer vaccine targeting patients with limited therapeutic options. This collaboration builds upon pioneering research conducted three decades ago, with the potential to initiate groundbreaking clinical trials for cancer patients.
In March 2021, Charles River Laboratories International Inc. expanded its capabilities by acquiring Cognate BioServices Inc., a leading provider of contract development services for autologous dendritic cell vaccines. This strategic acquisition enables Charles River Laboratories to offer integrated solutions to clients, combining manufacturing with essential analytical testing to streamline processes and accelerate the time-to-market for novel dendritic cell vaccine candidates.
Major companies operating in the dendritic cell cancer vaccine market are Dendreon Pharmaceuticals LLC, Celgene Corporation, Cognate BioServices Inc., APAC Biotech, Asterias Biotherapeutics Inc, Batavia Biosciences, Medigene AG, Zelluna Immunotherapy AS, Diakonos Oncology, Elios Therapeutics LLC, Northwest Biotherapeutics, Oncopep Inc., PDC*line Pharma SA, SillaJen Biotherapeutics Inc., VLP Therapeutics, ImmunityBio Inc., Celldex Therapeutics Inc., Bellicum Pharmaceuticals, Argos Therapeutics Inc., DCPrime, NuGenerex Immuno-Oncology
North America was the largest region in the dendritic cell cancer vaccine market in 2024. The regions covered in the dendritic cell cancer vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the dendritic cell cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The dendritic cell cancer vaccines market consists of sales of autologous dendritic cell vaccines, allogeneic dendritic cell vaccines, and experimental vaccines. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Dendritic Cell Cancer Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on dendritic cell cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for dendritic cell cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dendritic cell cancer vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Product: CreaVax; Sipuleucel-T (Provenge); Other Products
- 2) By Distribution Channel: Hospitals; Cancer Centers; Ambulatory Surgical Centers; Clinics
- 3) By Application: Pediatrics; Adults
- 4) By End User: Oncology; Research Institutions; Biopharmaceutical Companies
- Subsegments:
- 1) By Creavax: Creavax In Clinical Trials; Creavax Commercialization
- 2) By Sipuleucel-T (Provenge): Sipuleucel-T In Prostate Cancer; Sipuleucel-T Market Share; Sipuleucel-T Regulatory Approvals
- 3) By Other Products: Dcvax; Oncovax; GVAX; Other Experimental Dendritic Cell Vaccines
- Companies Mentioned: Dendreon Pharmaceuticals LLC; Celgene Corporation; Cognate BioServices Inc.; APAC Biotech; Asterias Biotherapeutics Inc
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Dendritic Cell Cancer Vaccine market Characteristics
3. Dendritic Cell Cancer Vaccine market Trends And Strategies
4. Dendritic Cell Cancer Vaccine market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market
5. Global Dendritic Cell Cancer Vaccine Growth Analysis And Strategic Analysis Framework
- 5.1. Global Dendritic Cell Cancer Vaccine PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Dendritic Cell Cancer Vaccine market Growth Rate Analysis
- 5.4. Global Dendritic Cell Cancer Vaccine Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Dendritic Cell Cancer Vaccine Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Dendritic Cell Cancer Vaccine Total Addressable Market (TAM)
6. Dendritic Cell Cancer Vaccine market Segmentation
- 6.1. Global Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- CreaVax
- Sipuleucel-T (Provenge)
- Other Products
- 6.2. Global Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Cancer Centers
- Ambulatory Surgical Centers
- Clinics
- 6.3. Global Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Pediatrics
- Adults
- 6.4. Global Dendritic Cell Cancer Vaccine market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oncology
- Research Institutions
- Biopharmaceutical Companies
- 6.5. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Creavax, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Creavax In Clinical Trials
- Creavax Commercialization
- 6.6. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Sipuleucel-T (Provenge), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Sipuleucel-T In Prostate Cancer
- Sipuleucel-T Market Share
- Sipuleucel-T Regulatory Approvals
- 6.7. Global Dendritic Cell Cancer Vaccine Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dcvax
- Oncovax
- GVAX
- Other Experimental Dendritic Cell Vaccines
7. Dendritic Cell Cancer Vaccine market Regional And Country Analysis
- 7.1. Global Dendritic Cell Cancer Vaccine market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Dendritic Cell Cancer Vaccine market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Dendritic Cell Cancer Vaccine market
- 8.1. Asia-Pacific Dendritic Cell Cancer Vaccine market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Dendritic Cell Cancer Vaccine market
- 9.1. China Dendritic Cell Cancer Vaccine market Overview
- 9.2. China Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Dendritic Cell Cancer Vaccine market
- 10.1. India Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Dendritic Cell Cancer Vaccine market
- 11.1. Japan Dendritic Cell Cancer Vaccine market Overview
- 11.2. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Dendritic Cell Cancer Vaccine market
- 12.1. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Dendritic Cell Cancer Vaccine market
- 13.1. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Dendritic Cell Cancer Vaccine market
- 14.1. South Korea Dendritic Cell Cancer Vaccine market Overview
- 14.2. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Dendritic Cell Cancer Vaccine market
- 15.1. Western Europe Dendritic Cell Cancer Vaccine market Overview
- 15.2. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Dendritic Cell Cancer Vaccine market
- 16.1. UK Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Dendritic Cell Cancer Vaccine market
- 17.1. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Dendritic Cell Cancer Vaccine market
- 18.1. France Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Dendritic Cell Cancer Vaccine market
- 19.1. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Dendritic Cell Cancer Vaccine market
- 20.1. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Dendritic Cell Cancer Vaccine market
- 21.1. Eastern Europe Dendritic Cell Cancer Vaccine market Overview
- 21.2. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Dendritic Cell Cancer Vaccine market
- 22.1. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Dendritic Cell Cancer Vaccine market
- 23.1. North America Dendritic Cell Cancer Vaccine market Overview
- 23.2. North America Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Dendritic Cell Cancer Vaccine market
- 24.1. USA Dendritic Cell Cancer Vaccine market Overview
- 24.2. USA Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Dendritic Cell Cancer Vaccine market
- 25.1. Canada Dendritic Cell Cancer Vaccine market Overview
- 25.2. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Dendritic Cell Cancer Vaccine market
- 26.1. South America Dendritic Cell Cancer Vaccine market Overview
- 26.2. South America Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Dendritic Cell Cancer Vaccine market
- 27.1. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Dendritic Cell Cancer Vaccine market
- 28.1. Middle East Dendritic Cell Cancer Vaccine market Overview
- 28.2. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Dendritic Cell Cancer Vaccine market
- 29.1. Africa Dendritic Cell Cancer Vaccine market Overview
- 29.2. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Dendritic Cell Cancer Vaccine market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Dendritic Cell Cancer Vaccine market Competitive Landscape And Company Profiles
- 30.1. Dendritic Cell Cancer Vaccine market Competitive Landscape
- 30.2. Dendritic Cell Cancer Vaccine market Company Profiles
- 30.2.1. Dendreon Pharmaceuticals LLC Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Celgene Corporation Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Cognate BioServices Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. APAC Biotech Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Asterias Biotherapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Dendritic Cell Cancer Vaccine market Other Major And Innovative Companies
- 31.1. Batavia Biosciences
- 31.2. Medigene AG
- 31.3. Zelluna Immunotherapy AS
- 31.4. Diakonos Oncology
- 31.5. Elios Therapeutics LLC
- 31.6. Northwest Biotherapeutics
- 31.7. Oncopep Inc.
- 31.8. PDC*line Pharma SA
- 31.9. SillaJen Biotherapeutics Inc.
- 31.10. VLP Therapeutics
- 31.11. ImmunityBio Inc.
- 31.12. Celldex Therapeutics Inc.
- 31.13. Bellicum Pharmaceuticals
- 31.14. Argos Therapeutics Inc.
- 31.15. DCPrime
32. Global Dendritic Cell Cancer Vaccine market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Dendritic Cell Cancer Vaccine market
34. Recent Developments In The Dendritic Cell Cancer Vaccine market
35. Dendritic Cell Cancer Vaccine market High Potential Countries, Segments and Strategies
- 35.1 Dendritic Cell Cancer Vaccine market In 2029 - Countries Offering Most New Opportunities
- 35.2 Dendritic Cell Cancer Vaccine market In 2029 - Segments Offering Most New Opportunities
- 35.3 Dendritic Cell Cancer Vaccine market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
